JPX Healthcare Drug Manufacturers - Specialty & Generic 4886.T

ASKA Pharmaceutical Holdings Co.,Ltd.

$ 2 294.00 -1.25 %

ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the research, development, production, and commercialization of medications, with a specific focus on endocrinology, obstetrics and gynecology, and urology. Within its animal health segment, ASKA manufactures, sells, imports, and exports a broad spectrum of veterinary products, such as medicines, medical equipment, animal feed and supplements, laboratory reagents, agricultural chemicals, industrial chemicals, hygiene products, and food items along with their raw materials. Beyond these activities, the company also performs clinical and biological testing and offers medical devices. Founded in 1920, ASKA Pharmaceutical Holdings Co.,Ltd. is headquartered in Tokyo, Japan.

CEO: Takashi Yamaguchi - https://www.aska-pharma-hd.co.jp

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 5 727.97

Loading data...

4886.T vs S&P500

Loading data...

No data available.

Quick ratio

1.45

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

12.00

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

191.09

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

8.01 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

5.05 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

6.30

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.05

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.00

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
3.12 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.45 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.03 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.